Published in Drug Week, November 3rd, 2006
This second study used a higher dose radiation than the first study and showed the same level of protection. Importantly, it also demonstrated a decrease in p53 accumulation. The p53 protein is a tumor suppressor that is involved in a number of inflammatory conditions and cancer.
In the first human study reported by PXL, EUK-189 had been shown to prevent erythema induced by UV irradiation. In this second study, EUK-189 applied...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2006-11-03)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.